title: The immunoreactive patient: Rejection and autoimmune disease.
abstract: 1. Despite highly potent immunosuppression regimens, there is a small cohort of patients at risk of graft failure due to rejection. 2. Steroid-resistant rejection is managed by the escalation of immunosuppression, but only one-third of patients with chronic rejection respond to this approach. 3. Interferon therapy for recurrent hepatitis C may induce an immunoreactive state and increase rejection rates. 4. Cyclosporine reduces the risk of recurrence of primary biliary cirrhosis but does not alter survival rates. 5. Patterns of primary sclerosing cholangitis recurrence are not affected by immunosuppression. 6. Autoimmune hepatitis recurrence and de novo autoimmune hepatitis are corticosteroid-responsive in most cases.
authors.affiliation: Institute of Liver Studies, King's College Hospital, London, United Kingdom. john.o'grady@kcl.ac.uk.
authors.forename: John
authors.initials: J
authors.lastname: O'Grady
mesh_terms: D015209:Cholangitis, Sclerosing / Q000453:epidemiology / Q000276:immunology*; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology*; D019693:Hepatitis, Autoimmune / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D008105:Liver Cirrhosis, Biliary / Q000453:epidemiology / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology*; D012307:Risk Factors